6 terminated. 6 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Terminated 6 |
| Phase 2 | 2 | Terminated 2 |
Follow Muscle Spasticity: new trials by email Literature Review of Muscle Spasticity trials Research Report on Muscle Spasticity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity Phase 2; Low Dose MYOBLOC (10,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo - Spasticity, Cerebrovascular Accident | Phase 2 / Phase 3 | Terminated | Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC | 32 | 2021-11-02 | 2026-05-27 |
| Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis Nabiximols, Placebo - Spasticity With Multiple Sclerosis | Phase 3 | Terminated | Jazz Pharmaceuticals | 56 | 2021-08-16 | 2024-12-11 |
| Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis Nabiximols, Placebo - Multiple Sclerosis (MS) | Phase 3 | Terminated | Jazz Pharmaceuticals | 139 | 2020-10-01 | 2024-05-08 |
| Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity Phase 2; Low Dose MYOBLOC (15,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo - Spasticity | Phase 2 / Phase 3 | Terminated | Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC | 40 | 2019-12-17 | 2026-05-22 |
| OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity onabotulinumtoxinA, placebo (normal saline) - Muscle Spasticity, Stroke | Phase 3 | Terminated | Allergan | 53 | 2014-05-01 | 2017-04-12 |
| MUltiple Sclerosis and Extract of Cannabis (MUSEC) Study standardized cannabis extract, Placebo - Muscle Spasticity | Phase 3 | Terminated | Institut fur Klinische Forschung, Germany | 279 | 2006-06-01 | 2015-03-25 |
Multiple Sclerosis (4) · Stroke (3) · Brain Injuries, Traumatic (2) · Hemiplegia (2) · Cerebral Palsy (1) · Pain (1)
Muscle Hypertonia (6) · Muscular Diseases (6) · Musculoskeletal Diseases (6) · Nervous System Diseases (6) · Neurologic Manifestations (6) · Neuromuscular Manifestations (6) · Pathological Conditions, Signs and Symptoms (6) · Signs and Symptoms (6) · Autoimmune Diseases (4) · Autoimmune Diseases of the Nervous System (4) · Demyelinating Autoimmune Diseases, CNS (4) · Demyelinating Diseases (4) · Immune System Diseases (4) · Brain Diseases (3) · Cardiovascular Diseases (3)
Clinical Trials, Phase II as Topic (2) · Clinical Trials, Phase III as Topic (2) · nabiximols (2) · rimabotulinumtoxinB (2) · Botulinum Toxins, Type A (1) · Saline Solution (1)
Jazz Pharmaceuticals (2) · Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC (2) · Allergan (1) · Institut fur Klinische Forschung, Germany (1)
United States (5) · Poland (4) · United Kingdom (3) · Czechia (2) · Hungary (2) · Canada (1) · Romania (1) · Spain (1)
Joseph T Hull, PhD (2) · John J Zajicek, Prof. (1)
2005 (1), 2019 (1)